Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Peterson

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|February 2, 2012
Hospital-physician alignment: making the relationship workKate Lovrien, Luke Peterson
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Crystallization of truncated hemolysin A from Proteus mirabilisLuke Bailey, Sean Agger, Luke Peterson, et al.
Expert Opinion on Drug Delivery|November 2, 2016
Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritisBarbara Domańska, Brenda VanLunen, Luke Peterson, et al.
The Journal of Rheumatology|May 3, 2018
PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab PegolJessica A Walsh, Terri Arledge, Tommi Nurminen, et al.
World Journal of Psychiatry|January 24, 2022
Mechanism of olfactory deficit in neurotrauma and its related affective distress: A narrative reviewMark Logan, Siddharth Kapoor, Luke Peterson, et al.
Dermatology and Therapy|August 27, 2020
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque PsoriasisAlice B Gottlieb, Valerie Ciaravino, Christopher Cioffi, et al.
Journal of Drugs in Dermatology : JDD|February 8, 2022
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With PsoriasisJerry Bagel, Daljit Tatla, Scarlett Hellot, et al.
Dermatology and Therapy|March 28, 2025
Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study DataJohn R Ingram, Jérémy Lambert, Valerie Ciaravino, et al.
Advances in Therapy|September 2, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b TrialAlice B Gottlieb, Richard B Warren, Matthias Augustin, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|February 2, 2012
Hospital-physician alignment: making the relationship workKate Lovrien, Luke Peterson
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Crystallization of truncated hemolysin A from Proteus mirabilisLuke Bailey, Sean Agger, Luke Peterson, et al.
Expert Opinion on Drug Delivery|November 2, 2016
Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritisBarbara Domańska, Brenda VanLunen, Luke Peterson, et al.
The Journal of Rheumatology|May 3, 2018
PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab PegolJessica A Walsh, Terri Arledge, Tommi Nurminen, et al.
World Journal of Psychiatry|January 24, 2022
Mechanism of olfactory deficit in neurotrauma and its related affective distress: A narrative reviewMark Logan, Siddharth Kapoor, Luke Peterson, et al.
Dermatology and Therapy|August 27, 2020
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque PsoriasisAlice B Gottlieb, Valerie Ciaravino, Christopher Cioffi, et al.
Journal of Drugs in Dermatology : JDD|February 8, 2022
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With PsoriasisJerry Bagel, Daljit Tatla, Scarlett Hellot, et al.
Dermatology and Therapy|March 28, 2025
Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study DataJohn R Ingram, Jérémy Lambert, Valerie Ciaravino, et al.
Advances in Therapy|September 2, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b TrialAlice B Gottlieb, Richard B Warren, Matthias Augustin, et al.
Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.
Pageof 3